May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Is Elevated Level of Soluble Endothelial Protein C Receptor a New Risk Factor for Retinal Vein Occlusion?
Author Affiliations & Notes
  • S. Kadayifcilar
    Ophthalmology,
    Hacettepe University School of Medicine, Ankara, Turkey
  • K. Gümüs
    Ophthalmology,
    Hacettepe University School of Medicine, Ankara, Turkey
  • B. Eldem
    Ophthalmology,
    Hacettepe University School of Medicine, Ankara, Turkey
  • O.I. Özcebe
    Hematology,
    Hacettepe University School of Medicine, Ankara, Turkey
  • S. Dündar
    Hematology,
    Hacettepe University School of Medicine, Ankara, Turkey
  • O. Saracbasi
    Biostatistics,
    Hacettepe University School of Medicine, Ankara, Turkey
  • Footnotes
    Commercial Relationships  S. Kadayifcilar, None; K. Gümüs, None; B. Eldem, None; O.I. Özcebe, None; S. Dündar, None; O. Saracbasi, None.
  • Footnotes
    Support  Hacettepe University Research Grant 04 D02 101 003
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 4051. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Kadayifcilar, K. Gümüs, B. Eldem, O.I. Özcebe, S. Dündar, O. Saracbasi; Is Elevated Level of Soluble Endothelial Protein C Receptor a New Risk Factor for Retinal Vein Occlusion? . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4051.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the systemic and thrombophilic risk factors involved in retinal vein occlusion (RVO) and to determine whether the elevated level of soluble endothelial protein C receptor (sEPCR) is a risk factor for retinal vein thrombosis. Methods: Fifty–six patients with central RVO (CRVO), 26 patients with branch RVO (BRVO) and 78 otherwise healthy sex– and age–matched subjects who presented with refractive errors, presbyopia, or cataract were enrolled in this study. After a written informed consent, all patients underwent complete ophthalmologic examination. Venous blood samples were taken after an overnight fast of at least 8 hours for the analysis of glucose, lipid profile, lipoprotein (a), homocysteine, activated partial thromboplastin time, fibrinogen, factor VIII, protein C activity, protein S activity, activated protein C resistance, antithrombin III activity, lupus anticoagulant, anti–cardiolipin antibody, anti–phospholipid antibody, sEPCR, factor V Leiden mutation, and prothrombin G20210A mutation. Results: Apart from hypertension, glaucoma, lipoprotein (a), homocysteine, and factor VIII, elevated level of sEPCR was found to be a risk factor for CRVO (odds ratio, 1.023; 95%confidence interval, 1.009–1.037; p=0.001) with logistic regression. Patients with CRVO had significantly higher levels of sEPCR than those of BRVO and controls (Mean levels (ng/ml): 144.0 ± 83.8, 116.8 ± 65.2, and 103.3 ± 56.1 respectively; p=0.021). Moreover, 31% of patients with CRVO had levels of sEPCR more than 200 ng/ml, while only 6% and 11% of patients had similar high levels in the control and BRVO groups, respectively. Conclusions:Besides known classical risk factors, elevated level of sEPCR seems to be an important candidate risk factor for especially CRVO.

Keywords: retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×